Welcome to our dedicated page for Sanofi SEC filings (Ticker: SNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sanofi's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sanofi's regulatory disclosures and financial reporting.
Sanofi (SNY) has filed a July 2025 Form 6-K that incorporates two press releases.
- 16 Jul 2025: Investigational complement inhibitor SAR446597 received FDA Fast Track designation for geographic atrophy secondary to age-related macular degeneration, potentially accelerating development and review.
- 22 Jul 2025: Sanofi announced an agreement to acquire Vicebio, a private company developing respiratory vaccines, to broaden its vaccines pipeline.
No financial statements, deal value, or timing details are included in the filing. Nonetheless, the regulatory milestone and pipeline-expanding acquisition underscore Sanofi’s strategic emphasis on specialty therapies and vaccines, areas that management views as key long-term growth drivers.
Sanofi (SNY) filed a Form 6-K to notify investors that its investigational monoclonal antibody riliprubart has received orphan-drug designation in two major markets during June 2025:
- United States (FDA) – for the prevention of antibody-mediated rejection in solid-organ transplantation (Press Release 25 Jun 2025).
- Japan (MHLW) – for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) (Press Release 30 Jun 2025).
Orphan-drug status can confer regulatory incentives such as market exclusivity (7 years in the U.S., up to 10 years in Japan), tax credits, fee waivers and a potentially faster approval pathway. Although the filing does not disclose clinical data, financial terms or timelines, the dual designation signals regulatory validation of riliprubart’s potential across two distinct immunological indications. No other material transactions, financial results or strategic changes are included in this 6-K.
Sanofi has reported three significant developments in their drug portfolio through Form 6-K filed on June 28, 2025:
- Dupixent superiority demonstrated over Xolair (omalizumab) in the first-ever phase 4 head-to-head respiratory study for treating chronic rhinosinusitis with nasal polyps in patients with coexisting asthma (June 15, 2025)
- FDA approval secured for Dupixent as the only targeted medicine for treating bullous pemphigoid, expanding its therapeutic applications (June 20, 2025)
- CHMP recommendation received for Sarclisa's EU approval to treat transplant-eligible newly diagnosed multiple myeloma (June 23, 2025)
These developments represent significant regulatory and clinical milestones for Sanofi's key drug products, particularly strengthening Dupixent's market position across multiple indications and advancing Sarclisa's potential availability in the EU market for multiple myeloma treatment.